Overview

Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis

Status:
Completed
Trial end date:
2018-05-07
Target enrollment:
Participant gender:
Summary
This is an exploratory study, which allows analysis of multiple immune parameters derived from peripheral blood mononuclear cells (PBMCs) from patients with relapsing remitting multiple sclerosis before and during immune-modulatory treatment with dimethyl fumarate in comparison to PBMCs from healthy subjects.
Phase:
Phase 4
Details
Lead Sponsor:
University Hospital Muenster
Collaborator:
Biogen
Treatments:
Dimethyl Fumarate